Literature DB >> 29504044

Weekly regimen of vitamin D supplementation is more efficacious than stoss regimen for treatment of vitamin D deficiency in children with chronic liver diseases.

Bikrant Bihari Lal1, Seema Alam2, Rajeev Khanna1, Dinesh Rawat1.   

Abstract

There are no evidence-based recommendations on the ideal dose and regimen for supplementation of vitamin D in children with chronic liver disease (CLD). This study aimed to compare the safety and efficacy of weekly and stoss regimens for treatment of vitamin D deficiency in these children. Children between the ages of 1 to 18 years with CLD and hypovitaminosis D defined by 25-OH vitamin D (25(OH)D) < 30µg/l were included. They were randomized to receive either stoss regimen (600,000 IU on day 1) or weekly (60,000 IU weekly) regimen of vitamin D. The 25(OH)D levels at 3 and 6 months were compared in the two groups. A total of 210 suspected cases of CLD were assessed for eligibility. Of a total of 67 children satisfying the inclusion criteria, 33 and 34 were randomized to receive stoss and weekly regimen, respectively. Final analysis included 28 children in each group. Clinical rickets was seen in 25.4% of children with hypovitaminosis D. The rise in levels of 25(OH)D at 3 months was higher with weekly regimen (34.3 ± 30.7 µg/l) as compared to stoss regimen (17.2 ± 11.5 µg/l) (p = 0.009). Rise at 6 months as compared to baseline was significantly higher with weekly regimen (30.7 ± 24µg/l) as compared to stoss regimen (11 ± 8.4 µg/l) (p < 0.001). Normal levels of 25(OH)D at 6 months were achieved in 24/28 (85.7%) of those receiving weekly regimen and 9/28 (32.1%) of those receiving stoss regimen (p < 0.001). With stoss therapy, 25(OH)D increased at 3 months as compared to baseline but thereafter dropped significantly at 6 months (p = 0.008).
CONCLUSION: Weekly regimen of vitamin D supplementation is more effective than stoss regimen for treatment of hypovitaminosis D in children with CLD. Once normal levels are achieved, child should be shifted to 60,000 IU per month as maintenance dose. What is Known: • Vitamin D deficiency is more common and severe in children with chronic liver diseases. • Currently used doses fail to achieve normal vitamin D levels in these children. What is New? • Weekly regimen of 60,000 IU of vitamin D3 is the most effective regimen for treating vitamin D deficiency in children with CLD. • Children with CLD should further receive maintenance dose of 60,000 IU every month.

Entities:  

Keywords:  Chronic liver disease; Stoss regimen; Vitamin D deficiency

Mesh:

Substances:

Year:  2018        PMID: 29504044     DOI: 10.1007/s00431-018-3123-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Gastroenterol Hepatol       Date:  2007-01-10       Impact factor: 11.382

Review 2.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

3.  Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia.

Authors:  Benjamin L Shneider; John C Magee; Jorge A Bezerra; Barbara Haber; Saul J Karpen; Trivellore Raghunathan; Philip Rosenthal; Kathleen Schwarz; Frederick J Suchy; Nanda Kerkar; Yumirle Turmelle; Peter F Whitington; Patricia R Robuck; Ronald J Sokol
Journal:  Pediatrics       Date:  2012-08-13       Impact factor: 7.124

Review 4.  D-livering the message: the importance of vitamin D status in chronic liver disease.

Authors:  Matthew T Kitson; Stuart K Roberts
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

5.  Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets.

Authors:  Yaşar Cesur; Hüseyin Caksen; Alpaslan Gündem; Ercan Kirimi; Dursun Odabaş
Journal:  J Pediatr Endocrinol Metab       Date:  2003 Oct-Nov       Impact factor: 1.634

6.  Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells.

Authors:  Allan M Ramirez; Cherry Wongtrakool; Teresa Welch; Andreas Steinmeyer; Ulrich Zügel; Jesse Roman
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-17       Impact factor: 4.292

7.  Treatment of hypovitaminosis D in infants and toddlers.

Authors:  Catherine M Gordon; Avery LeBoff Williams; Henry A Feldman; Jessica May; Linda Sinclair; Alex Vasquez; Joanne E Cox
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

8.  Prevalence of vitamin D deficiency in apparently healthy children in north India.

Authors:  Suresh Kumar Angurana; Renu Suthar Angurana; Gagan Mahajan; Neeraj Kumar; Vikas Mahajan
Journal:  J Pediatr Endocrinol Metab       Date:  2014-11       Impact factor: 1.634

9.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

Review 10.  Vitamin D and bone health in early life.

Authors:  Christian Mølgaard; Kim Fleischer Michaelsen
Journal:  Proc Nutr Soc       Date:  2003-11       Impact factor: 6.297

View more
  4 in total

1.  Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease.

Authors:  Natalie G Martin; Tarah Rigterink; Mustafa Adamji; Catherine L Wall; Andrew S Day
Journal:  Transl Pediatr       Date:  2019-01

2.  Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age.

Authors:  Samantha L Huey; Nina Acharya; Ashley Silver; Risha Sheni; Elaine A Yu; Juan Pablo Peña-Rosas; Saurabh Mehta
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

3.  Treatment of rickets and dyslipidemia in twins with progressive familial intrahepatic cholestasis type 2.

Authors:  Sunitha R Sura; Emily L Germain-Lee
Journal:  Int J Pediatr Endocrinol       Date:  2020-05-26

Review 4.  Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies.

Authors:  Seema Alam; Bikrant Bihari Lal
Journal:  World J Hepatol       Date:  2022-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.